Articles: 29.05 May 2018

Falling out of love with pills

Society loves pills. According to Wikipedia, they’ve been around since the 1500s. And we’ve seen more than a doubling of prescribing in primary care over the past 20 years, driven by a culture of single-disease evidence-based practice on the background of an ageing, increasingly multimorbid population

More details...

BAP consensus guidelines on autism spectrum disorder

The British Association for Psychopharmacology recently issued new guidelines on the assessment and treatment of autism spectrum disorder, based on consensus rather than systematic review. This article provides an overview of the main recommendations

More details...

Management of benign vulval dermatoses in primary care

Vulval dermatoses can be difficult to manage in primary care, and GPs need to be aware of the risk of malignancy. This article describes the most common types of benign vulval dermatoses encountered in primary care and their management, and discusses when referral to secondary care is required.

More details...

Is weight loss the future of type 2 diabetes treatment?

Achieving remission from type 2 diabetes was once only thought to be realistic for patients undergoing bariatric surgery. But this view is changing with early publication of results from the Diabetes Remission Clinical Trial (DiRECT) based in Scotland and Tyneside, which has found success through a strict low-calorie diet. This article discusses the implications of the study for the future of diabetes treatment

More details...

Diagnosing and managing agerelated macular degeneration

NICE’s new guideline on diagnosing and managing age-related macular degeneration in adults (NG82) aims to improve the speed at which people are diagnosed and treated to prevent sight loss. This article provides a summary of the guidance

More details...

Where next for social prescribing in England?

Social prescribing – the process of primary care professionals referring patients to a range of local non-clinical services – was the focus of a conference organised by the Westminster Health Forum and held in London in March. Joy Ogden reports on some of the highlights of the conference

More details...

Dupilumab for the treatment of atopic dermatitis

Dupilumab (Dupixent) is a new monoclonal antibody treatment licensed for use in adults with moderate to severe atopic dermatitis (eczema) who are candidates for systemic therapy. This article discusses its properties, efficacy and side-effects

More details...

Doesn’t it make you want to spit?

Getting patients to rinse their mouth with water – and then spit it out – is an important way of minimising both localised and systemic adverse effects of inhaled corticosteroids. But are we being explicit enough in our advice

More details...

Web design and marketing agency Leamington Spa